Drilldown: Medicines

Codeine (2)

Other values:

Search

None (47) · (multiple, generic dominant) (1) · Benzedrex (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Multiple OTC dietary supplement formulations (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Mu-opioid receptor agonist (4) · Potent mu-opioid receptor agonist (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

Search

None (58) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"' (1)

None (58) · 0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (58) · OTC tablets, sublingual tablets, gummies, liquid, extended-release tablets and capsules; common strengths 0.5, 1, 3, 5, 10 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (58) · 360 mg/day (1) · Not formally established (dietary supplement); doses above ~3-5 mg show no additional efficacy but increase next-day sedation risk (1)

None (58) · Oral (1) · PO (only formulation marketed in the US). (1) · sublingual (1)

None (58) · 30-60 minutes (immediate-release oral) (1) · 30–60 min (PO) (1)

None (58) · 3-4 hours (1) · 4–6 hours (1)

None (58) · 2.5–3 hours (1) · 30-50 minutes (short)'"`UNIQ--ref-00000021-QINU`"' (1)

None (58) · ~15% (oral; highly variable due to extensive and variable first-pass metabolism)'"`UNIQ--ref-00000022-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (58) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; endogenous hormone, but supplemental pharmacological doses are not well characterized in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (58) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Over-the-counter|OTC]] dietary supplement in the US ('''not FDA-regulated as a medicine'''; multiple studies show OTC products contain 50-470% of labeled melatonin content); [[USLegal:Prescription only|Rx-only]] in the EU and UK (1)